Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.68 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 6/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992908 | 0.85 | AOC3 (0.62) | CNR2AOC3MTORLRRK2PIK3CA | |
| SCHEMBL13136641 | 0.84 | CNR2 (0.71) | CNR2AOC3PIK3CAPIK3CDPIK3CG | |
| SCHEMBL12812386 | 0.83 | PIK3CA (0.52) | CNR2MTORLRRK2PIK3CAPIK3CD | |
| SCHEMBL12523755 | 0.82 | AOC3 (0.59) | CNR2AOC3MTORLRRK2PIK3CA | |
| SCHEMBL17221698 | 0.80 | CYP11B1 (0.57) | CNR2AOC3 | |
| SCHEMBL30827430 | 0.80 | CYP11B1 (0.57) | CNR2AOC3 | |
| SCHEMBL857231 | 0.80 | CYP11B1 (0.57) | CNR2AOC3 | |
| SCHEMBL16773016 | 0.80 | CNR2 (0.69) | CNR2ATR | |
| SCHEMBL16675789 | 0.79 | SMN1; SMN2 (0.54) | CNR2AOC3MTORATRATRIP | |
| SCHEMBL29551393 | 0.79 | AOC3 (0.56) | CNR2AOC3ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855489-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | CNR2 776/4885AOC3 2306/4885MTOR 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.